BioGend Therapeutics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	222.34	167.65	109.91	31.45	9.27
Revenue Growth (YoY)	32.62%	52.53%	249.51%	239.26%	565.40%
Cost of Revenue	62.18	37.14	20.29	8.67	6.21
Gross Profit	160.16	130.51	89.62	22.78	3.06
Selling, General & Admin	145.41	124.04	95.16	75.73	54.09
Research & Development	124.45	128.72	171	166.27	113.27
Operating Expenses	270.65	252.77	266.16	241.99	167.37
Operating Income	-110.5	-122.26	-176.54	-219.21	-164.31
Interest Expense	-0.15	-0.22	-0.26	-0.09	-0.02
Interest & Investment Income	8.04	6.07	6.92	4.59	2.88
Earnings From Equity Investments	-1.84	-2.46	-0.84	-	-11.35
Currency Exchange Gain (Loss)	-	-0	0.03	0.07	0.51
Other Non Operating Income (Expenses)	0.84	0.62	1.46	0.74	0.87
EBT Excluding Unusual Items	-103.61	-118.25	-169.22	-213.9	-171.4
Gain (Loss) on Sale of Investments	-	-10	-	-	26.7
Other Unusual Items	-	-	-	-	0.44
Pretax Income	-103.61	-128.25	-169.22	-213.9	-144.27
Income Tax Expense	-8.31	-8.31	-8.3	-8.4	-
Earnings From Continuing Operations	-95.3	-119.94	-160.92	-205.5	-144.27
Minority Interest in Earnings	10.69	3.47	4.59	21.04	5.78
Net Income	-84.61	-116.47	-156.33	-184.46	-138.49
Net Income to Common	-84.61	-116.47	-156.33	-184.46	-138.49
Shares Outstanding (Basic)	123	123	120	103	101
Shares Outstanding (Diluted)	123	123	120	103	101
Shares Change (YoY)	-0.37%	2.32%	16.69%	1.77%	15.90%
EPS (Basic)	-0.69	-0.95	-1.30	-1.79	-1.37
EPS (Diluted)	-0.69	-0.95	-1.30	-1.79	-1.37
Free Cash Flow	-65.52	-99.56	-164.76	-186.96	-137.47
Free Cash Flow Per Share	-0.53	-0.81	-1.37	-1.81	-1.36
Gross Margin	72.03%	77.85%	81.54%	72.44%	33.00%
Operating Margin	-49.70%	-72.93%	-160.63%	-697.11%	-1772.67%
Profit Margin	-38.05%	-69.47%	-142.23%	-586.58%	-1494.07%
Free Cash Flow Margin	-29.47%	-59.38%	-149.91%	-594.54%	-1483.13%
EBITDA	-60.73	-74.76	-125.21	-170.87	-137.9
EBITDA Margin	-27.31%	-44.59%	-113.92%	-	-
D&A For EBITDA	49.77	47.5	51.33	48.35	26.41
EBIT	-110.5	-122.26	-176.54	-219.21	-164.31
EBIT Margin	-49.70%	-72.93%	-160.63%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.